## **AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions and listings of claims in the application.

## **Listing of Claims**

1. to 39. (cancelled)

- 40. (New) A method of treating cancer in a patient, comprising administering to a patient in need thereof an effective amount of an anti-IL-13 antibody or an antigen binding fragment thereof that binds specifically to human IL-13, wherein said antibody or antigen binding fragment thereof competes with an antibody produced by hybridoma 228B/C-1 having ATCC Accession No. PTA-5657.
- 41. (New) The method of claim 40, wherein the anti-IL-13 antibody or antigen-binding fragment binds an epitope having the amino acid sequence ESLINVSG (SEQ ID NO:18) or YCAALESLINVS (SEQ ID NO:19).
- 42. (New) The method of claim 40 or 41, wherein the anti-IL-13 antibody or antigen-binding fragment comprises a light chain comprising a CDRL1 having the amino acid sequence of SEQ ID NO: 99, a CDRL2 having the amino acid sequence of SEQ ID NO:104; and a CDRL3 having the amino acid sequence of SEQ ID NO: 115.
- 43. (New) The method of claim 40 or 41, wherein the anti-IL-13 antibody or antigen-binding fragment comprises a heavy chain comprising a CDRH1 having the amino acid sequence of SEQ ID NO: 117, a CDRH2 having the amino acid sequence of SEQ ID NO: 123; and a CDRH3 having the amino acid sequence of SEQ ID NO: 135.
- 44. (New) The method of claim 43, wherein the anti-IL-13 antibody or antigen-binding fragment comprises a light chain comprising a CDRL1 having the amino acid sequence of SEQ ID NO: 99, a CDRL2 having the amino acid sequence of SEQ ID NO:104; and a CDRL3 having the amino acid sequence of SEQ ID NO: 115.
- 45. (New) The method of claim 40 or 41, wherein the anti-IL-13 antibody or antigen-

binding fragment comprises a light chain comprising the amino acid sequence of SEQ ID NO: 3, 142, 144 or 150; and a heavy chain comprising the amino acid sequence of SEQ ID NO: 4, 143, 145, 146, 147, 148 or 149.

- 46. (New) The method of claim 40 or 41, wherein the anti-IL-13 antibody or antigenbinding fragment comprises the amino acid sequence of SEQ ID NO: 142 or 143.
- 47. (New) The method of claim 40 or 41, wherein the anti-IL-13 antibody or antigen-binding fragment comprises a light chain comprising the amino acid sequence of SEQ ID NO: 142, and a heavy chain comprising the amino acid sequence of SEQ ID NO: 143.
- 48. (New) The method of claim 40 or 41, wherein the anti-IL-13 antibody or antigenbinding fragment comprises a heavy chain comprising:
  - (a) a CDRH1 having the amino acid sequence SEQ ID NO: 117, 118, 119, 120, 121 or 122;
  - (b) a CDRH2 having the amino acid sequence SEQ ID NO: 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133 or 134; and
  - (c) a CDRH3 having the amino acid sequence SEQ ID NO: 135, 136, 137, 138, 139, 140 or 141.
- 49. (New) The method of claim 40 or 41 wherein the anti-IL-13 antibody or antigenbinding fragment comprises a light chain comprising:
  - (a) a CDRL1 having the amino acid sequence SEQ ID NO: 99, 100, 101, 102 or 103;
  - (b) a CDRL2 having the amino acid sequence SEQ ID NO: 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, or 114; and
  - (c) a CDRL3 having the amino acid sequence of SEQ ID NO: 115 or 116.
- 50. (New) The method of claim 40 or 41, wherein the anti-IL-13 antibody or antigenbinding fragment is a monoclonal antibody.
- 51. (New) The method of claim 40 or 41, wherein the anti-IL-13 antibody or antigenbinding fragment is an IgG antibody or a fragment thereof.

- 52. (New) The method of claim 51, wherein the anti-IL-13 antibody or antigen-binding fragment is an IgG1, an IgG2, an IgG3 or an IgG4 antibody or a fragment thereof.
- 53. (New) The method of claim 40 or 41, wherein the anti-IL-13 antibody or antigenbinding fragment is a human antibody, a chimeric antibody or a humanized antibody or a fragment thereof.
- 54. (New) The method of claim 40 or 41, wherein the anti-IL-13 antibody or antigenbinding fragment is a single chain antibody.
- 55. (New) The method of claim 40 or 41, wherein the anti-IL-13 antibody mediates tumor cell killing by antibody dependent cell-mediated cytotoxicity and/or complement mediated cytotoxicity.
- 56. (New) The method of claim 40 or 41, wherein the anti-IL-13 antibody or antigen binding fragment is administered by inhalation, bolus injection, or infusion.
- 57. (New) The method of claim 40 or 41, wherein said cancer is Hodgkin's disease, skin cancer, stomach cancer, colon cancer, breast cancer, pancreatic cancer, liver cancer, prostate cancer, lung cancer, head-and-neck cancer, renal cell cancer, squamous cell carcinoma, AIDS-associated Kaposi's carcinoma or brain cancer.
- 58. (New) The method of claim 40 or 41, wherein the anti-IL-13 antibody is associated with a cytotoxic agent.
- 59. (New) The method of claim 58, wherein the cytotoxic agent is a radioisotope or a chemotherapeutic agent.
- 60. (New) A method of diagnosing a cancer or tumor that overexpresses IL-13 in a biological sample, comprising detecting overexpression of IL-13 in the biological sample taken from a patient suspected of having said cancer or tumor by contacting the biological sample with an anti-IL-13 antibody or antigen-binding fragment thereof that binds specifically to human IL-13, wherein said antibody competes with an antibody produced by hybridoma 228B/C-1 having ATCC Accession No. PTA-5657 for binding to IL-13.

- 61. (New) The method of claim 60, wherein the anti-IL-13 antibody or antigen-binding fragment binds an epitope having the amino acid sequence ESLINVSG (SEQ ID NO:18) or YCAALESLINVS (SEQ ID NO:19).
- 62. (New) The method of claim 60 or 61, wherein the anti-IL-13 antibody or antigen-binding fragment comprises a light chain comprising a CDRL1 having the amino acid sequence of SEQ ID NO: 99, a CDRL2 having the amino acid sequence of SEQ ID NO: 104; and a CDRL3 having the amino acid sequence of SEQ ID NO: 115.
- 63. (New) The method of claim 60 or 61, wherein the anti-IL-13 antibody or antigenbinding fragment comprises a heavy chain comprising a CDRH1 having the amino acid sequence of SEQ ID NO: 117, a CDRH2 having the amino acid sequence of SEQ ID NO: 123, and a CDRH3 having the amino acid sequence of SEQ ID NO: 135.
- 64. (New) The method of claim 63, wherein the anti-IL-13 antibody or antigen-binding fragment comprises a light chain comprising a CDRL1 having the amino acid sequence of SEQ ID NO: 99, a CDRL2 having the amino acid sequence of SEQ ID NO: 104; and a CDRL3 having the amino acid sequence of SEQ ID NO: 115.
- 65. (New) The method of claim 60 or 61, wherein the anti-IL-13 antibody or antigen-binding fragment comprises a light chain comprising the amino acid sequence of SEQ ID NO: 3, 142, 144 or 150; and said antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 4, 143, 145, 146, 147, 148 or 149.
- 66. (New) The method of claim 60 or 61, wherein the anti-IL-13 antibody or antigenbinding fragment comprises the amino acid sequence of SEQ ID NO: 142 or 143.
- 67. (New) The method of claim 60 or 61, wherein the anti-IL-13 antibody or antigen-binding fragment comprises a light chain comprising the amino acid sequence of SEQ ID NO: 142, and a heavy chain comprising the amino acid sequence of SEQ ID NO: 143.
- 68. (New) The method of claim 60 or 61, wherein the anti-IL-13 antibody or antigenbinding fragment is a human antibody, a chimeric antibody or a humanized antibody

U.S. Application No. 10/583,926 Preliminary Amendment and Response filed June 19, 2009

or a fragment thereof.

69. (New) The method of claim 68, wherein said cancer is Hodgkin's disease, skin cancer, stomach cancer, colon cancer, breast cancer, pancreatic cancer, liver cancer, prostate cancer, lung cancer, head-and-neck cancer, renal cell cancer, squamous cell carcinoma, AIDS-associated Kaposi's carcinoma or brain cancer.